Park Medi World
Listing performance
Scheduled dates
Tentative timetable — a past date is not confirmation the step completed
Grey market premium
Unofficial and indicative — not a forecast
3 observations recorded — too few to plot a trend.
Day-wise premium · 3 observations
| Date | GMP | % | Sauda | Est. listing | Gain / lot |
|---|---|---|---|---|---|
| 17 Dec 2025 | ₹0 | 0.00% | ₹0 | ₹162 | ₹0 |
| 16 Dec 2025 | ₹5 | +3.09% | ₹300 | ₹167 | ₹460 |
| 15 Dec 2025 | ₹3.5 | +2.16% | ₹200 | ₹165.5 | ₹322 |
Gain per lot assumes the premium holds to listing and that the application is allotted — allotment in an oversubscribed issue is a lottery, so it is indicative, not expected. Sauda is the rate paid for a submitted application itself.
Issue details
- IPO date
- 10 Dec 2025 – 12 Dec 2025
- Listing date
- 17 Dec 2025
- Face value
- ₹2 per share
- Issue price
- ₹162 per share
- Lot size
- 92 shares
- Issue type
- Book Building issue
- Listing at
- NSE
- Total issue size
- ₹920 Cr
- Market cap at offer price
- ₹6,997 Cr
- Promoter holding
- 95.55% → 82.89% pre-issue → post-issue
- ISIN
- INE119201023
- Registrar
- Kfin Technologies Ltd.
- Lead managers
- Nuvama Wealth Management Ltd.
- Registered office
- 12, Meera Enclave Near Keshopur, Bus Depot, Outer Ring Road, New Delhi
Reservation and application size
How the issue is split between investor categories, and what each may bid
| Investor category | Shares | % of net | % of total |
|---|---|---|---|
| Anchor investor · within QIB | 1,70,37,036 | — | — |
| Market maker | 0 | — | — |
Application size
Minimum 92 shares per lot, in multiples, at ₹162
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 1 | 92 | ₹14,904 |
| Retail (max) | 13 | 1,196 | ₹1,93,752 |
| S-HNI (min) | 14 | 1,288 | ₹2,08,656 |
| S-HNI (max) | 67 | 6,164 | ₹9,98,568 |
| B-HNI (min) | 68 | 6,256 | ₹10,13,472 |
Category limits
| Category | Bid size | Cut-off |
|---|---|---|
| Retail (RII) | Up to ₹2 lakh | Yes |
| Small HNI (sNII) | ₹2 lakh – ₹10 lakh | No |
| Big HNI (bNII) | Above ₹10 lakh | No |
| Employee | Up to ₹5 lakh | Yes |
Bidding at cut-off means accepting the final issue price without naming one. Only retail and employee applicants may do so.
Anchor investors
Institutional allocation placed a day before the issue opens, carved out of the QIB portion and locked in after listing.
Valuation and performance
Valuation at offer price
₹162 per share
| Metric | Pre-issue | Post-issue |
|---|---|---|
| EPS (₹) | 5.55 | 6.44 |
| P/E (×) | 29.19 | 25.16 |
| Price to book (×) | 6.09 | — |
| Market cap | — | ₹6,997 Cr |
Key performance indicators
Latest reported period
- Return on net worth
- 20.08%
- ROCE
- 17.47%
- Debt / equity
- 0.61
- PAT margin
- 15.30%
- EBITDA margin
- 26.71%
- NAV per share
- ₹26.58
- Price to book
- 6.09
Single period as reported. Year-on-year movement is in the financials table below, where every period is published.
About Park Medi World
Park Medi World Limited was incorporated in New Delhi on January 20, 2011 as Park Medi World Private Limited under the Companies Act, 1956, and was converted into a public limited company, renamed Park Medi World Limited, pursuant to a fresh certificate of incorporation dated December 20, 2024. Per the CRISIL Report commissioned for the Offer, it is the second largest private hospital chain in North India with an aggregate bed capacity of 3,000 beds as of March 31, 2025, and the largest private hospital chain in Haryana with 1,600 beds; bed capacity grew from 2,550 beds (March 31, 2023) to 3,250 beds (September 30, 2025), aided by acquisitions of eight hospitals adding 1,650 beds, and an ongoing NCLT-approved acquisition of Durha Vitrak (operating as Febris Multi Specialty Hospital, Narela, New Delhi) by subsidiary Blue Heavens. It runs 14 NABH-accredited multi-super specialty hospitals — eight in Haryana, three in Punjab, two in Rajasthan and one in New Delhi — with a pipeline of expansion in Ambala, Panchkula, Rohtak, New Delhi, Gorakhpur and Kanpur. The Company earns money from in-patient and out-patient hospital services: in Fiscal 2025 the in-patient department contributed 96.00% of revenue from operations, and government schemes and PSUs accounted for 88.46%, with insurance and self-pay making up the remainder. Restated consolidated revenue from operations was ₹13,935.70 million and restated profit after tax ₹2,132.15 million in Fiscal 2025. The Company will receive proceeds only from the Fresh Issue of the Offer; the Offer for Sale proceeds accrue to Promoter Selling Shareholder Dr. Ajit Gupta.
Company Analysis
from DRHPPark Medi World Limited operates a network of 14 NABH-accredited multi-super specialty hospitals under the 'Park' brand across North India, making it the second largest private hospital chain in North India by bed capacity and the largest in Haryana.
Park Medi World Limited was incorporated in New Delhi on January 20, 2011 as Park Medi World Private Limited under the Companies Act, 1956, and was converted into a public limited company, renamed Park Medi World Limited, pursuant to a fresh certificate of incorporation dated December 20, 2024. Per the CRISIL Report commissioned for the Offer, it is the second largest private hospital chain in North India with an aggregate bed capacity of 3,000 beds as of March 31, 2025, and the largest private hospital chain in Haryana with 1,600 beds; bed capacity grew from 2,550 beds (March 31, 2023) to 3,250 beds (September 30, 2025), aided by acquisitions of eight hospitals adding 1,650 beds, and an ongoing NCLT-approved acquisition of Durha Vitrak (operating as Febris Multi Specialty Hospital, Narela, New Delhi) by subsidiary Blue Heavens. It runs 14 NABH-accredited multi-super specialty hospitals — eight in Haryana, three in Punjab, two in Rajasthan and one in New Delhi — with a pipeline of expansion in Ambala, Panchkula, Rohtak, New Delhi, Gorakhpur and Kanpur. The Company earns money from in-patient and out-patient hospital services: in Fiscal 2025 the in-patient department contributed 96.00% of revenue from operations, and government schemes and PSUs accounted for 88.46%, with insurance and self-pay making up the remainder. Restated consolidated revenue from operations was ₹13,935.70 million and restated profit after tax ₹2,132.15 million in Fiscal 2025. The Company will receive proceeds only from the Fresh Issue of the Offer; the Offer for Sale proceeds accrue to Promoter Selling Shareholder Dr. Ajit Gupta.
Objects of the Issue
- Repayment/prepayment, in full or in part, of outstanding borrowings availed by our Company and our Subsidiaries ₹ 3,800.00 million p.19
- Funding capital expenditure for development of new hospital by our Subsidiary Park Medicity (NCR) ₹ 605.00 million p.19
- Funding capital expenditure for purchase of medical equipment by our Company and our Subsidiaries, Blue Heavens and Ratangiri ₹ 274.59 million p.19
- Unidentified inorganic acquisitions and general corporate purposes (GCP/unidentified inorganic acquisitions capped at 25% of Gross Proceeds each, together not exceeding 35%) ₹ 2,453.18 million p.19
Issue Structure
- Total Issue
- 56,790,123 Equity Shares of face value of ₹2 each aggregating up to ₹ 9,200.00 million (Offer constituted 13.15% of post-Offer paid-up equity share capital)
- Fresh Issue
- 47,530,864 Equity Shares of face value of ₹2 each aggregating up to ₹ 7,700.00 million
- Offer for Sale
- 9,259,259 Equity Shares of face value of ₹2 each aggregating up to ₹ 1,500.00 million by Dr. Ajit Gupta (Promoter Selling Shareholder)
- Price Band
- ₹154 – ₹162 per Equity Share (Floor Price ₹154; Cap Price ₹162); final Offer Price ₹162 per share
- Lot Size
- 92 Equity Shares and in multiples of 92 Equity Shares thereafter
- Face Value
- ₹2 each
Business Model
Revenue comes from the sale of healthcare services at its 14 'Park'-brand multi-super specialty hospitals, comprising in-patient hospital receipts (patients admitted for at least one overnight stay; 96.00% of Fiscal 2025 revenue from operations) and out-patient consultations, billed to self-paying patients, insurers, and primarily government schemes and public sector undertakings (Government Schemes and PSUs contributed 88.46% of Fiscal 2025 revenue from operations; Insurance 5.01%; Self-Pay 6.40%).
Business Segments
Promoters
| Name | Role | Pre-Issue | Post-Issue |
|---|---|---|---|
| Dr. Ajit Gupta | Promoter / Promoter Selling Shareholder | 86.22% | 74.59% |
| Dr. Ankit Gupta | Promoter | 9.33% | 8.31% |
| Nidhi Gupta | Member of Promoter Group | Negligible | Negligible |
Leadership
Auto-extracted from the company's DRHP using AI, with each fact linked to its source passage (hover any row to see the quote & page). Provided for research only, not investment advice — verify against the official DRHP before relying on it.